BASEL, SWITZERLAND--(Marketwire - June 17, 2008) - Speedel Holding Ltd. (SWX: SPPN) highlighted today that Novartis is to expand the clinical trial programme with SPP100 (aliskiren; Rasilez/Tekturna[1]) to study organ protection potential beyond the already shown powerful reduction of blood pressure. Novartis announced details of two new long-term outcome studies in its landmark ASPIRE HIGHER clinical trial programme. This series of trials now form the largest and most far-reaching cardio-renal outcomes programme worldwide.
